Doral, FL, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, is negotiating on medical device promotion options, and plans to launch a clinical study with HIV-seropositive and AIDS patients in the near future.

As previously announced, ETST will initiate the distribution of its medical devices in Djibouti and Morocco (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech--Inc--Announces-New-Agreement-with-Axcelon-Biopolymers-Corp--for-Distribution-of-Nanoderm-trade--Medical-Device--amp--Advances-with-Its-MSN-2-Medical-Device?id=170151&b=y ). As the company waits for regulatory clearance to launch in North America, the company will have already collected valuable sales data from international markets. ETST is also developing an imminent partnership agreement to reach the Vietnamese market for the MSN-2 medical device. Additionally, original branding and graphical elements will be coming in soon (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech--Inc--Signs-Contract-with-Absolu-to-Advance-Phase-2-Rollout-on-MSN-2-Medical-Device?id=166272&b=y), and the Nanoderm™ medical device which was developed by a member of the ETST advisory board, Dr. Chandra Panchal (Founder, Chairman, Chief Executive Officer and Chief Scientific Officer of Axcelon Biopolymer: http://axcelonbp.com/companay/board-of-directors/ ). Only some details remain to be discussed and the new Vietnamese market partner will be announced before year end.

The company is also in discussions to introduce its high-grade CBD hemp oil in the primary launch countries. The first samples of MSN-2 and Nanoderm™ are being sent to Djibouti, Morocco, and Vietnam, in order to start negotiations with local authorities and partners alike.

In Vietnam the products will be presented directly to hospital administrators and physicians by ETST’s new American partner who is of Vietnamese origin. This forthcoming partner has been a distributor of medical devices for many years, and saw a huge opportunity working with Earth Science Tech in its early growth phases.

New clinical study of HIV seropositive and AIDS-infected patients

ETST is planning a clinical study of HIV-seropositive people and AIDS-infected patients in the hope of making as much a difference in the lives of as many people as is possible. The company sees a tremendous opportunity to help people who are infected with HIV, because they suffer from oxidative-related stress and inflammation that are caused by their medical condition. Many HIV patients suffer from chronic pain that requires them to take opioids, which many even become addicted to. ETST’s CBD rich hemp oil may help them to diminish the quantity of pain relief drugs they need to take and help with the withdrawal from opioids. This project is in line with the clinical study that was just announced this week (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech-Commences-Pre-Launch--Double-Blind-Human-Clinical-Trials-for-New-CBD-Formula-to-Fight-U-S--Opioid-Epidemic?id=176428&b=y ).

In addition, HIV patients are often afflicted by neurological complications that originate from neuro-inflammation. The neuronal protection activity of ETST CBD rich hemp oil has already been proven in vitro by DV Biologics:

http://www.otcmarkets.com/stock/ETST/news/DV-Biologics--a-Leading-Biological-Company--Reports-Earth-Science-Tech--ETST--High-Grade-Hemp-CBD--Cannabidiol--Oil-Reduces-Oxidative-Stress-and-Lipid-Peroxidation-on-Human-Brain-Cells-In-Vitro?id=107954&b=y 

The administration of CBD may not only relieve many symptoms resulting from HIV infection and associated medication, but it may also help to slow the development of other HIV-associated diseases. This clinical assay will lay the foundation for the creation of the first CBD rich Hemp Oil product improved with other natural molecules to relieve symptoms and retard diseases in HIV patients.

Further updates concerning the third clinical study and other ETST projects will be issued soon.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. 

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305)-546-7640 
Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305)-615-2118